Stereotactic radiosurgery for limited brain mets is currently widely employed across virtually all histologies, including small cell lung cancer (SCLC). This is largely borne of common sense decisions to use today’s technology to avoid the potentially devastating neurocognitive side effects of whole brain radiation. Despite patients with SCLC being excluded from most prospective trials of SRS, available data indicates intracranial disease control is comparable between SCLC and other histologies. Here is another retrospective review looking at outcomes following SRS for 337 SCLC brain mets across 70 patients. | Wang, Adv Radiat Oncol 2023
